Standard Biotools (LAB) Accumulated Expenses (2010 - 2026)

Standard Biotools (LAB) has 17 years of Accumulated Expenses data on file, last reported at $15.7 million in Q1 2026.

• Quarterly Accumulated Expenses rose 67.96% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (up 67.96% YoY) and the FY2025 annual result came in at $2.9 million, down 70.96% from the prior year.
• Accumulated Expenses grew to $15.7 million in Q1 2026 per LAB's latest filing, from $2.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $31.7 million in Q3 2024 and bottomed at $708000.0 in Q2 2025.
• The 5-year median for Accumulated Expenses is $8.0 million (2022), against an average of $11.3 million.
• The widest annual swing landed in 2024, when Accumulated Expenses jumped 1069.23%; it then slumped 94.94% in 2025.
• Tracing LAB's Accumulated Expenses over 5 years: stood at $6.2 million in 2022, then surged by 240.39% to $21.0 million in 2023, then plunged by 52.23% to $10.0 million in 2024, then plunged by 70.96% to $2.9 million in 2025, then surged by 437.86% to $15.7 million in 2026.
• Per Business Quant, the three latest LAB Accumulated Expenses figures stand at $15.7 million (Q1 2026), $2.9 million (Q4 2025), and $30.8 million (Q3 2025).

Peer Comparison